Celladon (CLDN) Stock Pummeled After Negative Trial Results, Downgrade

Shares of Celladon Corp. (CLDN) were down -10.10 or -73.83 percent to $3.56 per share in Monday's premarket, after news over the weekend that the company's drug for advanced heart failure had failed to meet primary and secondary endpoints in trials. In addition, due to the news, the stock was downgraded significantly by an analyst. ... READ MORE Read the rest of Celladon (CLDN) Stock Pummeled After Negative Trial Results, Downgrade at InvestorGuide.com .